Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30

$0.59+0.00 (+0.29%)

Close on Nov 11, 2026Market cap $164.37MP/E –Yield –

Humacyte total assets

Total assets on the balance sheet at the end of each period.

Humacyte's total assets was $125.57M at Sep 30, 2026. For fiscal 2025 it was $116.37M, down 15.6% from the year before. The highest annual figure on record is $286.53M in fiscal 2021.

Annual total assets

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$116.37M	-15.6%
FY2024	Dec 31, 2024	$137.87M	+7.5%
FY2023	Dec 31, 2023	$128.22M	-37.2%
FY2022	Dec 31, 2022	$204.30M	-28.7%
FY2021	Dec 31, 2021	$286.53M	+168.6%
FY2020	Dec 31, 2020	$106.69M	–

Quarterly total assets

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$125.57M	+37.2%
Q2 FY2026	Jun 30, 2026	$138.09M	-0.5%
Q1 FY2026	Mar 31, 2026	$110.56M	-32.0%
Q4 FY2025	Dec 31, 2025	$116.37M	-15.6%
Q3 FY2025	Sep 30, 2025	$91.51M	-20.3%
Q2 FY2025	Jun 30, 2025	$138.80M	+0.4%
Q1 FY2025	Mar 31, 2025	$162.55M	+0.7%
Q4 FY2024	Dec 31, 2024	$137.87M	+7.5%
Q3 FY2024	Sep 30, 2024	$114.76M	-23.2%
Q2 FY2024	Jun 30, 2024	$138.28M	-17.7%
Q1 FY2024	Mar 31, 2024	$161.47M	-11.8%
Q4 FY2023	Dec 31, 2023	$128.22M	-37.2%
Q3 FY2023	Sep 30, 2023	$149.39M	-34.0%
Q2 FY2023	Jun 30, 2023	$168.11M	-31.8%
Q1 FY2023	Mar 31, 2023	$182.98M	-30.8%
Q4 FY2022	Dec 31, 2022	$204.30M	-28.7%
Q3 FY2022	Sep 30, 2022	$226.22M	-25.4%
Q2 FY2022	Jun 30, 2022	$246.37M	+145.1%
Q1 FY2022	Mar 31, 2022	$264.47M	+162.7%
Q4 FY2021	Dec 31, 2021	$286.53M	+168.6%
Q3 FY2021	Sep 30, 2021	$303.36M	+199.4%
Q2 FY2021	Jun 30, 2021	$100.51M	–
Q1 FY2021	Mar 31, 2021	$100.67M	–
Q4 FY2020	Dec 31, 2020	$106.69M	–
Q3 FY2020	Sep 30, 2020	$101.32M	–